

Table 3. Summary of the relative potencies of the shuffled IFN- α and control compounds in the Huh7 EMCV antiviral assay

Sample [†]	Mean log EC ₅₀		n	Mean EC ₅₀ , ng/ml	Fold over IFN- α 2b [‡]	Fold over IFN-con1 [‡]	P value sample vs IFN-con1
B9X16 *	-1.40	0.302	6	0.0394	30	14	<0.0001
B9X14 *	-1.37	0.338	7	0.0429	27	13	<0.0001
B9X28 *	-1.33	0.399	6	0.0468	25	12	<0.0001
B9X25 *	-1.31	0.142	6	0.0492	24	11	<0.0001
B9X23 *	-1.24	0.210	8	0.0574	21	10	<0.0001
B9X18 *	-1.11	0.323	6	0.0775	15	7.1	<0.0001
B9X22 *	-1.05	0.142	4	0.0895	13	6.2	<0.0001
B9.1.1 *	-1.03	0.196	5	0.0942	12	5.9	<0.0001
B9X17 *	-0.970	0.079	6	0.107	11	5.2	<0.0001
B9X27 *	-0.902	0.231	5	0.125	9.4	4.4	<0.0001
B9X12 *	-0.871	0.245	6	0.134	8.8	4.1	<0.0001
B9.1.2 *	-0.871	0.281	6	0.135	8.7	4.1	<0.0001
B9X26 *	-0.803	0.265	3	0.158	7.5	3.5	<0.0001
B9X24 *	-0.759	0.220	5	0.174	6.8	3.2	<0.0001
B9X15 *	-0.565	0.132	4	0.272	4.3	2.0	0.000772
IFN-con1	-0.258	0.333	7	0.553	2.1	1.0	-
IFN- α 2b *	0.071	0.314	8	1.18	1.0	0.47	<0.0001

The samples are listed in order of decreasing antiviral potency. The dash indicates not applicable.

[†]The mean log EC₅₀ values of those interferon samples marked with an asterisk are statistically different at the 95% confidence level from the mean log EC₅₀ value of IFN-con1 in the Huh7 EMCV assay based on a two-way ANOVA and Fisher's least significant difference post hoc test ($\alpha = 0.05$). The Hill slopes and (SD) are: IFN- α 2b 1.08 (0.18), IFN-con1 1.11 (0.33), B9X14 2.02 (0.62), B9X25 2.46 (0.71).

[‡]Fold improvements were calculated as a ratio of mean EC₅₀ (ng/ml) values relative to IFN- α 2b or IFN-con1.